There was no association between Bax expression and p53nac in either patient group (data not shown). CRCs with negative or low Bax immunostaining were significantly

associated with CRCs that demonstrated frame-shift mutations at the Bax (G) 8 tract (20 of 23, 87%) as compared to CRCs without this mutation (25 of 60, 41%) (data not shown). In addition, most CRCs with poor differentiation had low Bax expression in the surgery-alone group (χ2, P= 0.0005) (Table 2). Figure 2 Examples of immunohistochemical expression of Bax, Bcl-2, and p53nac in colorectal adenocarcinomas Inhibitors,research,lifescience,medical and adjacent benign epithelium. Examples of immunostaining of the adjacent benign colorectal epithelium are presented for Bax expression Inhibitors,research,lifescience,medical (Panel-A, x20), … Table 2 Correlations between expression of Bax, Bcl-2 and p53nac and the characteristics of treated and untreated patients The median survival of the 5-FU treated group of patients with low Bax expression was 25 months relative to 5 months for surgery-alone patients with low Bax expression (Table 3). The median survival for 5-FU treated

patients with high Bax Inhibitors,research,lifescience,medical expression was 25 months relative to 56 months for surgery-alone patients with high Bax expression (Table 3). Kaplan-Meier analyses demonstrated a Rigosertib solubility dmso significant association between high Bax expression and better patient survival in the surgery-alone group (log rank P=0.006) (Fig 3A). Although there was no Inhibitors,research,lifescience,medical significant association between

Bax expression status and patient survival in the 5-FU treated group, patients with decreased Bax expression had improved survival (overall log rank P=0.211) (Fig 3B). Figure 3 Correlation of Bax and Bcl-2 expression with overall survival of colorectal cancer patients undergoing surgery alone or treated with 5-FU-based adjuvant therapy after surgery. The overall survival of patients with high Bax expression was compared Inhibitors,research,lifescience,medical to patients … Table 3 Median survival (in months) of patient groups based on the status of expression of Bax, Bcl-2, and p53nac Bcl-2 immunophenotypic expression analysis Immunoreactivity for Bcl-2 was localized in the cytoplasm; overall, the staining was homogenous. The staining in intra-tumoral lymphocytes was used as an internal control (Fig 2D-F). Of the patients, 46% had high Levetiracetam levels of Bcl-2 expression (27 5-FU-treated patients and 24 surgery-alone patients). There were no significant differences in the incidence of deaths due to CRCs in the Bcl-2 low and high expressors of among the 5-FU-treated or surgery-alone patients (Table 1). However, the median survival was higher (63.15 months) for surgery-alone patients with high levels of Bcl-2 expression as compared to those with low expression (17.61 months). There was no significant difference in the median survival of 5-FU treated patients with low or high Bcl-2 expression (Table 3).